Mammography remains the mainstay of screening for primary breast cancer, however, some limitations persists in women with dense breast, in its inability to differentiate a benign from a malignant lesion, and in its heavy reliance on the radiologists' skill. Breast specific gamma imaging, which evaluates the functional images rather than anatomic images seen in mammography, addresses these limitations and can be a potential adjunct in screening for breast cancer. This meta-analysis aims to determine the diagnostic accuracy of breast specific gamma imaging for diagnosing breast cancer in women who are high risk. We searched PUBMED (1999-2009) and Google Scholar (1999-2009) for diagnostic accuracy studies that compared breast specific gamma imaging with histopathologic diagnosis of breast cancer in high risk women. Citation searches and screening of references of included studies were conducted. Two authors searched citations that correlated with the criteria using a data collection form. The methodological quality was then assessed by three authors using the QUADAS method. HSROC meta-analytical tool was used to estimate summary ROC curves. Four studies with 360 participants and 411 lesions were included. Breast specific gamma imaging has a high sensitivity (84%-97%) and specificity (60%-86%). SROC shows the included studies have high overall accuracy. Breast specific gamma imaging has high diagnostic accuracy in detecting breast cancer in women at high risk.

Human ; Female ; Breast Neoplasms ; Neoplasms ; Neoplasms By Site ; Breast ; Mammography ; Roc Curve ; Radiologists ; Sensitivity And Specificity

Nuclear medicine departments use the camera-based method for determining glomerular filtration rate (GFR) with 99mTc-DPTA. Camera based techniques provide a fast and convenient way of determining GFR with excellent reproducubility however its accuracy remains in question. The accuracy of camera-based renal scintigraphy depends on an attenuation correlation from estimating for renal depth and an attenuation correction from estimating for renal depth and an attenuation coefficient. Algorithms were formulated by Tonnesen, Taylor, and Inoue to calculate the estimated renal depth through multiple stepwise linear regression analysis. The goal of this study was to analyze the accuracy of these algorithms in Filipino patients. Renal depth was determined from CT scans of 41 consecutive patients. We calculated the mean absolute error of the estimated kidney depths and compared them with each other to determine the accuracy of each algorithm. The Tonnesen algorithm had the highest mean absolute error of 1.25 cm plus minus 0.88 cm in the left kidney estimates while the Taylor algorithm had the lowest mean absolute error of 0.81 cm plus minus 0.58 cm in the left kidney estimate and 1.04 cm plus minus 0.82 cm in the right kidney estimate (p-value = 0.01 left kidney estimates and p-value = 0.02 right kidney estimates). The Tonnesen algorithm was the least accurate in predicting kidney depth. There was no significant difference between the Taylor and Inoue algorithms, which were more accurate in predicting kidney depth
Human ; Male ; Female ; KIDNEY ; UROGENITAL SYSTEM ; URINARY TRACT ; GLOMERULAR FILTRATION RATE ; DIAGNOSIS ; DIAGNOSTIC TECHNIQUES AND PROCEDURES ; DIAGNOSTIC TECHNIQUES, UROLOGICAL ; KIDNEY FUNCTION TESTS ; RENAL SCINTIGRAPHY

Background: Breast cancer is the second most common malignancy globally. This study is a systematic review and meta-analysis assessing whole-body PET/CT using 18F-FDG in detecting breast carcinoma distant metastases as an update to the study of Xu et al. Objective: To determine the diagnostic accuracy of whole-body PET/CT in distant metastasis detection among breast cancer patients. Methods: The MEDLINE database was systematically searched for articles evaluating whole-body PET/CT in distant metastasis detection among breast cancer patients. Sensitivity, specificity, likelihood ratios and predictive values were derived by the three independent readers. Summary receiver operating characteristic curves were plotted. Results: Fifteen studies (n=4175) were included with pooled sensitivities, specificities, positive and negative likelihood ratios, positive and negative predictive values (with 95% confidence intervals) of 0.98 (0.97-0.99), 0.98 (0.98-0.99), 86.6 (63.6-117.9), 0.01 (0.01-0.02), 0.94 (0.92-0.95) and 0.99 (0.995-0-.998), respectively. Pooled positive and negative predictive values with a prevalence of 13.6% are 0. 93 and 0.99, respectively. Conclusion Whole-body PET/CT with 18F-FDG provides excellent detection of distant metastases in breast cancer and is recommended in assessing patients in earlier stages of the disease, not only in the later stages, especially in more aggressive tumors.
Fluorodeoxyglucose F18 ; Carcinoma ; Meta-analysis ; Breast Neoplasms

INTRODUCTION: 68Ga-PSMA PET is an effective imaging modality in the evaluation of prostate cancer. However, there is limited data on its use in the evaluation of therapeutic response, particularly in radioligand therapy. OBJECTIVE: Our aim is to investigate the diagnostic accuracy of 68Ga-PSMA PET hybrid imaging in evaluating response to 177Lu-PSMA therapy in patients with mCRPC compared with the standard use of serum PSA. METHODOLOGY: A systematic review was done according to the Cochrane diagnostic accuracy reviews guidelines and the PRISMA checklist of literature from January 2015 to August 2020. Literature search, study selection, and data extraction were conducted by 2 reviewers. Statistical analysis of data was done using Meta-DiSc v1.4 RESULTS: A total of 5 studies were included following screening. A total of 128 patients were included in the review. Using PSA response as the reference standard, the pooled sensitivity and specificity of 68Ga-PSMA PET hybrid imaging to evaluate treatment response to 177Lu-PSMA therapy was 85% (Cl: 74 to 92%) and 74% (Cl: 62 to 84%), respectively. The computed diagnostic accuracy was 79.7%. CONCLUSION 68Ga-PSMA PET hybrid imaging is an effective diagnostic procedure in evaluating treatment response to 177Lu-PSMA therapy ligand therapy with good sensitivity, specificity, and diagnostic accuracy.
Gallium ; lutetium ; prostatic neoplasms